The cataplexy pharmaceutical sector stands at a pivotal moment, with unprecedented investment flowing into research initiatives and therapeutic development programs. This rare neurological condition, characterized by sudden muscle weakness episodes triggered by strong emotions, presents unique challenges that innovative companies are addressing through groundbreaking scientific approaches and novel treatment methodologies. Investment Climate and Market Valuation… Read.